In an 8-week randomized trial, astaxanthin (20 mg/day) reduced disease activity (DAS-28), improved quality of life (HAQ), and lowered inflammatory markers (ESR, CRP) in rheumatoid arthritis patients. Limited effect on IL-6 and pain. Overall beneficial adjunct therapy.
